About this trial
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.
Eligibility criteria
Qualifiers
Clinically established or probable PD
Clinical Diagnostic Criteria for Parkinson's Disease
Peak-of-dose levodopa-induced dyskinesia.
Stable antiparkinsonian medicine for at least four weeks.
Disqualifiers
Psychiatric disorders.
Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin).
Regular usage of benzodiazepines and opioids (more than once per week).
History of neurological disease other than Parkinson's disease.
Trial design
Treatments tested in this trial
- active TMS
- sham TMS